Etrasimod Performs Well in Phase Phase 2b Trial of Adult Atopic Dermatitis
Nearly one-third of participants in the 2 mg etrasimod group achieved clear or almost clear skin, as defined by the validated Investigator Global Assessment (vIGA), the FDA endpoint for Phase 3 registration, according to topline results from Arena’s Phase 2b ADVISE clinical trial evaluating etrasimod for the moderate-to-severe atopic dermatitis (AD).
Mount Sinai Dermatologists Use Tape Strips to Map Immune Changes in Common Skin Disease
Jun 10, 2025 View All Press Releases
Mount Sinai Experts Author Landmark ‘Seminar’ on Atopic Dermatitis (Eczema) in The Lancet
Feb 13, 2025 View All Press Releases
